Displaying publications 61 - 80 of 573 in total

Abstract:
Sort:
  1. Foo CY, Nadia Mansor NA, Erng T, Mohamed MS, Mahadevan G, Lau G, et al.
    Value Health Reg Issues, 2025 Mar;46:101059.
    PMID: 39580723 DOI: 10.1016/j.vhri.2024.101059
    OBJECTIVES: This study quantified the health and economic benefits of improving low-density lipoprotein cholesterol (LDL-C) control in Malaysian patients with established atherosclerotic cardiovascular disease (ASCVD). It aimed to inform policy discussions and healthcare planning for effective ASCVD management.

    METHODS: A deterministic, prevalence-based model was used to project the annual health burden and direct medical costs associated with recurrent ASCVD events over a 10-year horizon. The target population included adults (≥30 years) with established ASCVD and uncontrolled LDL-C levels (>1.8 mmol/L). The model comprised 3 modules: population size projection, recurrent ASCVD risk calculation (by means of the Secondary Manifestations of ARTerial disease [SMART] risk model), and direct medical and productivity cost estimation. The current status quo and a scenario with a 50% improvement in mean LDL-C were compared.

    RESULTS: We projected over 800 000 adults with established ASCVD in 2023, increasing to approximately 1.4 million by 2032. Under the status quo, about 55 000 recurrent ASCVD events were expected within 10 years, with significant direct medical costs and productivity losses. Improved LDL-C control could potentially reduce recurrent events by 7000 cases (13% reduction), prevent 2100 premature deaths, and save approximately 32 400 years of life. Economically, this could lead to a reduction of approximately 72 million MYR in direct medical costs and a gain of approximately 132.4 million MYR in productivity over a decade.

    CONCLUSIONS: Optimizing LDL-C control in high-risk patients with ASCVD presents a critical opportunity to reduce health and economic burdens in Malaysia.

    Matched MeSH terms: Cardiovascular Diseases/economics; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/prevention & control
  2. Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, et al.
    Am J Clin Nutr, 2020 04 01;111(4):795-803.
    PMID: 31965140 DOI: 10.1093/ajcn/nqz348
    BACKGROUND: Eggs are a rich source of essential nutrients, but they are also a source of dietary cholesterol. Therefore, some guidelines recommend limiting egg consumption. However, there is contradictory evidence on the impact of eggs on diseases, largely based on studies conducted in high-income countries.

    OBJECTIVES: Our aim was to assess the association of egg consumption with blood lipids, cardiovascular disease (CVD), and mortality in large global studies involving populations from low-, middle-, and high-income countries.

    METHODS: We studied 146,011 individuals from 21 countries in the Prospective Urban Rural Epidemiology (PURE) study. Egg consumption was recorded using country-specific validated FFQs. We also studied 31,544 patients with vascular disease in 2 multinational prospective studies: ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects with Cardiovascular Disease). We calculated HRs using multivariable Cox frailty models with random intercepts to account for clustering by study center separately within each study.

    RESULTS: In the PURE study, we recorded 14,700 composite events (8932 deaths and 8477 CVD events). In the PURE study, after excluding those with history of CVD, higher intake of egg (≥7 egg/wk compared with <1 egg/wk intake) was not significantly associated with blood lipids, composite outcome (HR: 0.96; 95% CI: 0.89, 1.04; P-trend = 0.74), total mortality (HR: 1.04; 95% CI: 0.94, 1.15; P-trend = 0.38), or major CVD (HR: 0.92; 95% CI: 0.83, 1.01; P-trend = 0.20). Similar results were observed in ONTARGET/TRANSCEND studies for composite outcome (HR 0.97; 95% CI: 0.76, 1.25; P-trend = 0.09), total mortality (HR: 0.88; 95% CI: 0.62, 1.24; P-trend = 0.55), and major CVD (HR: 0.97; 95% CI: 0.73, 1.29; P-trend = 0.12).

    CONCLUSIONS: In 3 large international prospective studies including ∼177,000 individuals, 12,701 deaths, and 13,658 CVD events from 50 countries in 6 continents, we did not find significant associations between egg intake and blood lipids, mortality, or major CVD events. The ONTARGET and TRANSCEND trials were registered at clinicaltrials.gov as NCT00153101. The PURE trial was registered at clinicaltrials.gov as NCT03225586.

    Matched MeSH terms: Cardiovascular Diseases/blood; Cardiovascular Diseases/drug therapy; Cardiovascular Diseases/metabolism*; Cardiovascular Diseases/mortality*
  3. Rahman MA, Abdullah N, Aminudin N
    Crit Rev Biotechnol, 2016 Dec;36(6):1131-1142.
    PMID: 26514091
    Alzheimer's disease (AD) and cardiovascular diseases (CVD) share common etiology and preventive strategies. As the population of old-aged people is increasing worldwide, AD complications tend to afflict global healthcare budget and economy heavily. CVD is the prime cause of global mortality and remains a grave threat to both the developed and the developing nations. Mushroom bio-components may be promising in controlling both diseases. Based mainly on in vitro, ex vivo, cell line and animal studies, this review interprets the polypharmaceutic role of mushrooms treating AD and CVD.
    Matched MeSH terms: Cardiovascular Diseases/therapy*
  4. Raffa H, Sorefan A, Sorefan M
    Med J Malaysia, 1988 Mar;43(1):28-33.
    PMID: 3244316
    Matched MeSH terms: Cardiovascular Diseases/surgery*
  5. Rostam MA, Piva TJ, Rezaei HB, Kamato D, Little PJ, Zheng W, et al.
    Clin Exp Pharmacol Physiol, 2015 Feb;42(2):117-24.
    PMID: 25377120 DOI: 10.1111/1440-1681.12335
    Peptidyl-prolyl cis/trans isomerases (PPIases) are a conserved group of enzymes that catalyse the conversion between cis and trans conformations of proline imidic peptide bonds. These enzymes play critical roles in regulatory mechanisms of cellular function and pathophysiology of disease. There are three different classes of PPIases and increasing interest in the development of specific PPIase inhibitors. Cyclosporine A, FK506, rapamycin and juglone are known PPIase inhibitors. Herein, we review recent advances in elucidating the role and regulation of the PPIase family in vascular disease. We focus on peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1), an important member of the PPIase family that plays a role in cell cycle progression, gene expression, cell signalling and cell proliferation. In addition, Pin1 may be involved in atherosclerosis. The unique role of Pin1 as a molecular switch that impacts on multiple downstream pathways necessitates the evaluation of a highly specific Pin1 inhibitor to aid in potential therapeutic drug discovery.
    Matched MeSH terms: Cardiovascular Diseases/metabolism*
  6. Choy KW, Murugan D, Mustafa MR
    Pharmacol Res, 2018 06;132:119-129.
    PMID: 29684674 DOI: 10.1016/j.phrs.2018.04.013
    Endoplasmic reticulum (ER) is the main organelle for the synthesis, folding, and processing of secretory and transmembrane proteins. Pathological stimuli including hypoxia, ischaemia, inflammation and oxidative stress interrupt the homeostatic function of ER, leading to accumulation of unfolded proteins, a condition referred to as ER stress. ER stress triggers a complex signalling network referred as the unfolded protein response (UPR). Extensive studies have demonstrated that ER stress plays an important role in the pathogenesis of various cardiovascular diseases such as heart failure, ischemic heart disease and atherosclerosis. The importance of natural products in modern medicine are well recognized and continues to be of interests as a source of novel lead compounds. Natural products targeting components of UPR and reducing ER stress offers an innovative strategic approach to treat cardiovascular diseases. In this review, we discussed several therapeutic interventions using natural products with potential cardiovascular protective properties targeting ER stress signalling pathways.
    Matched MeSH terms: Cardiovascular Diseases/drug therapy*
  7. Ching SM, Chia YC, Lim HM
    J Hypertens, 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e56.
    PMID: 27753921
    Conference abstract:
    OBJECTIVE: This study aims to determine the relationship of long term visit to visit variability (VVV) of SBP and cardiovascular disease (CVD) in a primary care setting.
    DESIGN AND METHOD: This is a retrospective study of a cohort of 1416 patients over a period of 10 years (1998-2007). Demographic data, three monthly clinic BP readings and CVD events were captured from patient records. We derived the mean BP and VVV of SBPs for each subject and divided them into three groups defined as non hypertension, developed hypertension along the 10-year follow-up and persistent hypertension. We examined differences in cardiovascular events across these groups.
    RESULTS: Mean age of the participants at baseline was 56.5 ± 10.1 years, 34.6% were males. Table 1 describes mean SBP, BPV and CVD events of the study population.Those with both low mean SBP and low BPV have the lowest CVD events, conversely those with both high mean SBP and high BPV have highest CVD events. In those patients with the same mean SBP, whether high or low, those with higher BPV have more events than those with lower BPV. However patients with low mean SBP but high BPV have more CVD events compared with those patients with high mean SBP but low BPV (p = 0.04) suggesting BPV is more important than mean SBP in causing CVD events.We used ROC of VVV SBP to identify the cut off point of 12.9 mmHg as the indicator for increase in CVD events.
    CONCLUSIONS: In our study, we found that patients with hypertension have higher BPV than normotensive subjects. Furthermore those with higher BPV also had more CVD events. As such, we should prioritize lowering not only mean systolic BP but lowering BPV as well. Long term VVV SBP should be another target in the management of patients with hypertension.
    Matched MeSH terms: Cardiovascular Diseases*
  8. Isayeva G, Rieznik L, Buriakovska O, Vovchenko M, Emelyanova N, Shalimova A
    Wiad Lek, 2019;72(12 cz 1):2315-2323.
    PMID: 32124746
    OBJECTIVE: Introduction: Despite significant advances in prevention and treatment, cardiovascular disease remains the main cause of mortality and disability in Europe. This is largely due to the low level of commitment to doctors' recommendations for drug treatment and lifestyle modification. The aim of the study was to compare the effectiveness of group and individual training in the basics of medical knowledge to control the main risk factors for cardiovascular disease in patients.

    PATIENTS AND METHODS: Materials and methods: The study included 210 patients with high and very high cardiovascular risk. The first group consisted of 75 patients who studied at the School of Health 'Fundamentals of Healthy Lifestyle'. The second group consisted of 75 patients who were offered individual counseling. The control group consisted of 60 individuals. Patients in both groups were examined before and after the end of the course.

    RESULTS: Results and conclusions: We conducted a general clinical examination, determined anthropometric parameters, blood pressure (BP), glucose, cholesterol and its fractions in the blood. It has been established that the group training of patients with high and very high cardiovascular risk in Schools of Health 'Fundamentals of Healthy Lifestyle' promotes better BP control, but does not significantly affect the lipid metabolism. Individual training for patients with high and very high cardiovascular risk leads to a significant reduction in BP levels, improved lipid metabolism, increased physical activity, and improved quality of life.

    Matched MeSH terms: Cardiovascular Diseases*
  9. Tan KX, Pan S, Jeevanandam J, Danquah MK
    Int J Pharm, 2019 Mar 10;558:413-425.
    PMID: 30660748 DOI: 10.1016/j.ijpharm.2019.01.023
    Cardiovascular ailments are the foremost trigger of death in the world today, including myocardial infarction and ischemic heart diseases. To date, extraordinary measures have been prescribed, from the perspectives of both conventional medical therapies and surgeries, to enforce cardiac cell regeneration post cardiac traumas, albeit with limited long-term success. The prospects of successful heart transplants are also grim, considering exorbitant costs and unavailability of suitable donors in most cases. From the perspective of cardiac revascularization, use of nanoparticles and nanoparticle mediated targeted drug delivery have garnered substantial attention, attributing to both active and passive heart targeting, with enhanced target specificity and sensitivity. This review focuses on this aspect, while outlining the progress in targeted delivery of nanomedicines in the prognosis and subsequent therapy of cardiovascular disorders, and recapitulating the benefits and intrinsic challenges associated with the incorporation of nanoparticles. This article categorically provides an overview of nanoparticle-mediated targeted delivery systems and their implications in handling cardiovascular diseases, including their intrinsic benefits and encountered procedural trials and challenges. Additionally, the solicitations of aptamers in targeted drug delivery with identical objectives, are presented. This includes a detailed appraisal on various aptamer-navigated nanoparticle targeted delivery platforms in the diagnosis and treatment of cardiovascular maladies. Despite a few impending challenges, subject to additional investigations, both nanoparticles as well as aptamers show a high degree of promise, and pose as the next generation of drug delivery vehicles, in targeted cardiovascular therapy.
    Matched MeSH terms: Cardiovascular Diseases/drug therapy*
  10. Balasingam M, Ebrahim J, Ariffin IA
    Indian Heart J, 2017 Mar-Apr;69(2):252-254.
    PMID: 28460775 DOI: 10.1016/j.ihj.2017.01.010
    Telemedicine, ie 'the delivery of healthcare and sharing of medical knowledge using telecommunication systems' has penetrated every field of medicine. As a result, tele-echocardiography, the study of the heart via telemedicine started expanding. Ironically, space became the next frontier for mankind's new innovations and technology pursuit. However, the microgravity environment of space is known to be challenging to astronauts hearts. As such, new tele-echocardiography techniques have evolved. The main aim was to research a system that can be operated by a layperson but still be able to provide high yield diagnostic information in real time to specialists on earth. This spin-off space technology is recognized to have a positive impact, especially in developing countries with vast terrain. It is now utilized in hospitals and other terrestial locations where patients in remote regions can have their hearts analysed and data relayed to specialists in bigger centres for interpretation and further management.
    Matched MeSH terms: Cardiovascular Diseases/diagnosis*
  11. Balakumar P, Anand-Srivastava MB, Jagadeesh G
    Pharmacol Res, 2017 11;125(Pt A):1-3.
    PMID: 28711403 DOI: 10.1016/j.phrs.2017.07.003
    Matched MeSH terms: Cardiovascular Diseases/metabolism
  12. Shafiq M, Fong AYY, Tai ES, Nang EEK, Wee HL, Adam J, et al.
    Int J Epidemiol, 2018 10 01;47(5):1399-1400g.
    PMID: 30165399 DOI: 10.1093/ije/dyy168
    Matched MeSH terms: Cardiovascular Diseases/epidemiology*
  13. Nurliyana Juhan, Yong Zulina Zubairi, Zarina Mohd Khalid, Ahmad Syadi Mahmood Zuhdi
    MATEMATIKA, 2018;34(101):15-23.
    MyJurnal
    Cardiovascular disease (CVD) includes coronary heart disease, cerebrovascular disease (stroke), peripheral artery disease, and atherosclerosis of the aorta. All females face the threat of CVD. But becoming aware of symptoms and signs is a great challenge since most adults at increased risk of cardiovascular disease (CVD) have no symptoms or obvious signs especially in females. The symptoms may be identified by the assessment of their risk factors. The Bayesian approach is a specific way in dealing with this kind of problem by formalizing a priori beliefs and of combining them with the available observations. This study aimed to identify associated risk factors in CVD among female patients presenting with ST Elevation Myocardial Infarction (STEMI) using Bayesian logistic regression and obtain a feasible model to describe the data. A total of 874 STEMI female patients in the National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry year 2006-2013 were analysed. Bayesian Markov Chain Monte Carlo (MCMC) simulation approach was applied in the univariate and multivariate analysis. Model performance was assessed through the model calibration and discrimination. The final multivariate model of STEMI female patients consisted of six significant variables namely smoking, dyslipidaemia, myocardial infarction (MI), renal disease, Killip class and age group. Females aged 65 years and above have higher incidence of CVD and mortality is high among female patients with Killip class IV. Also, renal disease was a strong predictor of CVD mortality. Besides, performance measures for the model was considered good. Bayesian logistic regression model provided a better understanding on the associated risk factors of CVD for female patients which may help tailor prevention or treatment plans more effectively.
    Matched MeSH terms: Cardiovascular Diseases*
  14. Wong XY, Sena-Torralba A, Álvarez-Diduk R, Muthoosamy K, Merkoçi A
    ACS Nano, 2020 03 24;14(3):2585-2627.
    PMID: 32031781 DOI: 10.1021/acsnano.9b08133
    Nanotheranostics is one of the biggest scientific breakthroughs in nanomedicine. Most of the currently available diagnosis and therapies are invasive, time-consuming, and associated with severe toxic side effects. Nanotheranostics, on the other hand, has the potential to bridge this gap by harnessing the capabilities of nanotechnology and nanomaterials for combined therapeutics and diagnostics with markedly enhanced efficacy. However, nanomaterial applications in nanotheranostics are still in its infancy. This is due to the fact that each disease has a particular microenvironment with well-defined characteristics, which promotes deeper selection criteria of nanomaterials to meet the disease needs. In this review, we have outlined how nanomaterials are designed and tailored for nanotheranostics of cancer and other diseases such as neurodegenerative, autoimmune (particularly on rheumatoid arthritis), and cardiovascular diseases. The penetrability and retention of a nanomaterial in the biological system, the therapeutic strategy used, and the imaging mode selected are some of the aspects discussed for each disease. The specific properties of the nanomaterials in terms of feasibility, physicochemical challenges, progress in clinical trials, its toxicity, and their future application on translational medicine are addressed. Our review meticulously and critically examines the applications of nanotheranostics with various nanomaterials, including graphene, across several diseases, offering a broader perspective of this emerging field.
    Matched MeSH terms: Cardiovascular Diseases/drug therapy*
  15. Armas Rojas NB, Lacey B, Soni M, Charles S, Carter J, Varona-Pérez P, et al.
    BMC Public Health, 2021 05 27;21(1):963.
    PMID: 34039286 DOI: 10.1186/s12889-021-10911-9
    BACKGROUND: Cardiovascular disease accounts for about one-third of all premature deaths (ie, age cardiovascular mortality in this population remains unclear.

    METHODS: In 1996-2002, 146,556 adults were recruited from the general population in five areas of Cuba. Participants were interviewed, measured (height, weight and blood pressure) and followed up by electronic linkage to national death registries until Jan 1, 2017; in 2006-08, 24,345 participants were resurveyed. After excluding all with missing data, cardiovascular disease at recruitment, and those who died in the first 5 years, Cox regression (adjusted for age, sex, education, smoking, alcohol and, where appropriate, BMI) was used to relate cardiovascular mortality rate ratios (RRs) at ages 35-79 years to SBP, diabetes and BMI; RR were corrected for regression dilution to give associations with long-term average (ie, 'usual') levels of SBP and BMI.

    RESULTS: After exclusions, there were 125,939 participants (mean age 53 [SD12]; 55% women). Mean SBP was 124 mmHg (SD15), 5% had diabetes, and mean BMI was 24.2 kg/m2 (SD3.6); mean SBP and diabetes prevalence at recruitment were both strongly related to BMI. During follow-up, there were 4112 cardiovascular deaths (2032 ischaemic heart disease, 832 stroke, and 1248 other). Cardiovascular mortality was positively associated with SBP (>=120 mmHg), diabetes, and BMI (>=22.5 kg/m2): 20 mmHg higher usual SBP about doubled cardiovascular mortality (RR 2.02, 95%CI 1.88-2.18]), as did diabetes (2.15, 1.95-2.37), and 10 kg/m2 higher usual BMI (1.92, 1.64-2.25). RR were similar in men and in women. The association with BMI and cardiovascular mortality was almost completely attenuated following adjustment for the mediating effect of SBP. Elevated SBP (>=120 mmHg), diabetes and raised BMI (>=22.5 kg/m2) accounted for 27%, 14%, and 16% of cardiovascular deaths, respectively.

    CONCLUSIONS: This large prospective study provides direct evidence for the effects of these major risk factors on cardiovascular mortality in Cuba. Despite comparatively low levels of these risk factors by international standards, the strength of their association with cardiovascular death means they nevertheless exert a substantial impact on premature mortality in Cuba.

    Matched MeSH terms: Cardiovascular Diseases*
  16. Razali NNM, Ng CT, Fong LY
    Planta Med, 2019 Nov;85(16):1203-1215.
    PMID: 31539918 DOI: 10.1055/a-1008-6138
    Centella asiatica, a triterpene-rich medicinal herb, is traditionally used to treat various types of diseases including neurological, dermatological, and metabolic diseases. A few articles have previously reviewed a broad range of pharmacological activities of C. asiatica, but none of these reviews focuses on the use of C. asiatica in cardiovascular diseases. This review aims to summarize recent findings on protective effects of C. asiatica and its active constituents (asiatic acid, asiaticoside, madecassic acid, and madecassoside) in cardiovascular diseases. In addition, their beneficial effects on conditions associated with cardiovascular diseases were also reviewed. Articles were retrieved from electronic databases such as PubMed and Google Scholar using keywords "Centella asiatica," "asiatic acid," "asiaticoside," "madecassic acid," and "madecassoside." The articles published between 2004 and 2018 that are related to the aforementioned topics were selected. A few clinical studies published beyond this period were also included. The results showed that C. asiatica and its active compounds possess potential therapeutic effects in cardiovascular diseases and cardiovascular disease-related conditions, as evidenced by numerous in silico, in vitro, in vivo, and clinical studies. C. asiatica and its triterpenes have been reported to exhibit cardioprotective, anti-atherosclerotic, antihypertensive, antihyperlipidemic, antidiabetic, antioxidant, and anti-inflammatory activities. In conclusion, more clinical and pharmacokinetic studies are needed to support the use of C. asiatica and its triterpenes as therapeutic agents for cardiovascular diseases. Besides, elucidation of the molecular pathways modulated by C. asiatica and its active constituents will help to understand the mechanisms underlying the cardioprotective action of C. asiatica.
    Matched MeSH terms: Cardiovascular Diseases/drug therapy*
  17. Chia YC
    Singapore Med J, 2011 Feb;52(2):116-23.
    PMID: 21373738
    Cardiovascular Disease (CVD) is the leading cause of death in both developed and developing countries. While it is relatively easy to identify those who are obviously at high risk and those at the lowest risk for CVD, it is often the large group of individuals with what appears to be modestly abnormal risk factors who contributes most to the burden of CVD. This is where estimation of CVD risk is necessary. Many tools for risk assessment have been devised. All these risk scores have their own inherent advantages and disadvantages. Furthermore, they may also not be directly applicable to a local population. Ideally, each country should have its own risk score that takes into account other factors as well. In the interim, it is worthwhile to be familiar with one of these scores, select one that is most appropriate for your patient and discuss treatment options based on the estimated risk.
    Matched MeSH terms: Cardiovascular Diseases/epidemiology*
  18. Hamdy O, Barakatun-Nisak MY
    Endocrinol Metab Clin North Am, 2016 12;45(4):799-817.
    PMID: 27823606 DOI: 10.1016/j.ecl.2016.06.010
    Medical nutrition therapy (MNT) is a key component of diabetes management. The importance of balancing macronutrients, reducing carbohydrate load, lowering glycemic index, and implementing an overall healthy dietary pattern are emerging as better approaches for MNT in diabetes. Recent research points to improved glycemic control, reduction in body weight, and improvement in many cardiovascular risk factors when these approaches are provided by registered dietitians or health care providers. This review article discusses the current evidence about the role of sensible nutrition in diabetes management. Specific eating plans for weight reduction and for patients with type 1 diabetes are also discussed.
    Matched MeSH terms: Cardiovascular Diseases/complications
  19. Bradshaw L, Koumanov F, Berry S, Betts JA, Gonzalez J
    Exp Physiol, 2023 Apr;108(4):543-548.
    PMID: 36809567 DOI: 10.1113/EP091005
    Cardiovascular disease (CVD) is the leading cause of death worldwide. Physical activity interventions improve almost all modifiable CVD risk factors, but the effect of physical activity on low density lipoprotein cholesterol (LDL-C) is uncertain. This may be due to lack of research on the feeding status in which the physical activity is performed. The aim of this study is to investigate the effect of fasted versus fed exercise on LDL-C concentrations in males and females. One hundred healthy participants, equal males and females, aged between 25 and 60 years will be recruited and will undergo a home-based 12-week exercise intervention. After baseline testing, participants will be randomized to a fasted exercise (exercise after an 8-h fast) or fed exercise (exercise 90-180 min after ingestion of 1 g kg-1 CHO) group and will perform 50 min of moderate intensity exercise (e.g., 95% heart rate of lactate threshold 1) three times a week either before or after a high carbohydrate (1 g kg-1 ) meal. Participants will visit the laboratory again at week 4 and week 12 and measurements will be taken for body composition, resting blood pressure, fasting blood glucose, lipid profiles and systemic inflammation, lactate threshold, and 14-day blood glucose control.
    Matched MeSH terms: Cardiovascular Diseases*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links